BioVaxys invitations particular person and institutional traders, in addition to advisors and analysts, to attend on-line at www.VirtualInvestorConferences.com
DATE:
TIME:
LINK: https://bit.ly/3XjDJkL
BioVaxys can be obtainable for scheduled 1×1 conferences all through the day on
It’s endorsed that on-line traders pre-register and run the net system verify to expedite participation and obtain occasion updates.
Be taught extra concerning the occasion at www.virtualinvestorconferences.com.
Latest Firm Highlights
- In early 2024, BioVaxys acquired your complete portfolio of discovery, preclinical and scientific growth stage property in oncology, infectious illness, antigen desensitization, and different immunological fields based mostly on the DPX™ immune educating platform expertise, developed by the previous Canadian biotechnology firm, IMV (OTC:) Inc.
- BioVaxys executed a binding Letter of Intent in
July 2024 with AP Visionaries, Inc. ofOntario (“APVI”) to collectively develop a proprietary DPX™ formulation to deal with the pressing want for a remedy to deal with or alleviate the doubtless life-threatening threat of sure meals allergic reactions, specifically these triggered by publicity to peanut/tree nuts or eggs. BioVaxys and APVI are conducting the examine in collaboration with The Schroeder Allergy and Immunology Analysis Institute (“SAIRI”) at McMaster College inOntario . - BioVaxys Licensees Zoetis (NYSE:) and SpayVac-for-Wildlife, Inc., are each near submitting product registrations in animal well being purposes for vaccines using BioVaxys’ novel antigen supply platform. BioVaxys is slated to obtain royalties on gross sales of merchandise by each firms.
- BioVaxys not too long ago highlighted the potential of its novel lipid-in-oil supply platform, DPX™, throughout a number of infectious illness research and introduced its plans for partnering and additional growth. DPX™ is a patented supply platform that may incorporate a variety of bioactive molecules to provide focused, long-lasting immune responses enabled by varied formulated elements. The DPX platform facilitates antigen supply to regional lymph nodes and has been demonstrated to induce strong and sturdy T cell and B cell responses in pre-clinical and scientific research for each most cancers and infectious illness.
About BioVaxys Know-how Corp.
BioVaxys Know-how Corp. (www.biovaxys.com) is a clinical-stage biopharmaceutical firm devoted to enhancing affected person lives with novel immunotherapies based mostly on its DPX™ immune-educating expertise platform and its HapTenix © “neoantigen” tumor cell assemble platform, for treating cancers, infectious illness, antigen desensitization, and different immunological illnesses. DPX™ is a patented supply platform that may incorporate a variety of bioactive molecules to provide focused, long-lasting immune responses enabled by varied formulated elements. The DPX platform facilitates antigen supply to regional lymph nodes and has been demonstrated to induce strong and sturdy T cell and B cell responses in pre-clinical and scientific research for each most cancers and infectious illness. The Firm’s scientific stage pipeline contains maveropepimut-S (MVP-S), based mostly on the DPX™ platform, and is in Section II scientific growth for superior Relapsed-Refractory Diffuse Giant B Cell Lymphoma (DLBCL) and platinum resistant Ovarian Most cancers. MVP-S delivers antigenic peptides from survivin, a well-recognized most cancers antigen generally overexpressed in superior cancers, and likewise delivers an innate immune activator and a common CD4 T cell helper peptide. MVP-S has been nicely tolerated and has demonstrated outlined scientific profit in a number of most cancers indications in addition to the activation of a focused and sustained, survivin-specific anti-tumor immune response. BioVaxys can also be creating DPX™+SurMAGE, a dual-targeted immunotherapy combining antigenic peptides for each the survivin and MAGE-A9 most cancers proteins to elicit immune responses to those two distinct most cancers antigens concurrently, DPX™-RSV for Respiratory Syncytial Virus, DPX™+peanut antigen for peanut allergy prophylaxis, and BVX-0918, a personalised immunotherapeutic vaccine utilizing it proprietary HapTenix © “neoantigen” tumor cell assemble platform for refractive late-stage ovarian most cancers. BioVaxys frequent shares are listed on the CSE below the inventory image “BIOV” and commerce on the Frankfurt Bourse (FRA: 5LB) and within the US (OTCQB: BVAXF). For extra info, go to www.biovaxys.com and join with us on X and LinkedIn.
About Digital Investor Conferences ®
Digital Investor Conferences (VIC) is the main proprietary investor convention sequence that gives an interactive discussion board for publicly traded firms to seamlessly current on to traders.
Offering a real-time investor engagement resolution, VIC is particularly designed to supply firms extra environment friendly investor entry. Replicating the elements of an on-site investor convention, VIC presents firms enhanced capabilities to attach with traders, schedule focused one-on-one conferences and improve their shows with dynamic video content material. Accelerating the following stage of investor engagement, Digital Investor Conferences delivers main investor communications to a worldwide community of retail and institutional traders.
ON BEHALF OF THE BOARD
Signed “
Telephone: +1 740 358 0555
Cautionary Statements Concerning Ahead Trying Data
This press launch contains sure “forward-looking info” and “forward-looking statements” (collectively “forward-looking statements”) inside the which means of relevant Canadian and
These forward-looking statements replicate the beliefs, opinions and projections on the date the statements are made and are based mostly upon quite a lot of assumptions and estimates, primarily the belief that BioVaxys can be profitable in creating and testing vaccines, that, whereas thought-about cheap by the Firm, are inherently topic to important enterprise, financial, aggressive, political and social uncertainties and contingencies together with, primarily however with out limitation, the chance that BioVaxys’ vaccines is not going to show to be efficient and/ or is not going to obtain the required regulatory approvals. On the subject of BioVaxys’ enterprise, there are a selection of dangers that would have an effect on the event of its biotechnology merchandise, together with, with out limitation, the necessity for extra capital to fund scientific trials, its lack of working historical past, uncertainty about whether or not its merchandise will full the lengthy, advanced and costly scientific trial and regulatory approval course of for approval of latest medication needed for advertising approval, uncertainty about whether or not its autologous cell vaccine immunotherapy could be developed to provide secure and efficient merchandise and, if that’s the case, whether or not its vaccine merchandise can be commercially accepted and worthwhile, the bills, delays and uncertainties and issues usually encountered by growth stage biopharmaceutical companies, monetary and growth obligations below license preparations in an effort to shield its rights to its merchandise and applied sciences, acquiring and defending new mental property rights and avoiding infringement to 3rd events and their dependence on manufacturing by third events.
The Firm doesn’t assume any obligation to replace the forward-looking statements of beliefs, opinions, projections, or different elements, ought to they alter, besides as required by legislation.
BioVaxys Know-how Corp.
(740) 358 0555
https://www.biovaxys.com/contact
Digital Investor Conferences
OTC Markets Group
(212) 220-2221
[email protected]
Emblem: https://mma.prnewswire.com/media/2503982/Edge_Medical.jpg